Drug Trial Radar · NCT05508334
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 30, 2023
Primary completion
Nov 26, 2025
Study completion Nov 26, 2025
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to allow RC88 treatment of patients with advanced solid tumours to assess the safety and tolerability of clinical pharmacology studies
Conditions
- Advanced Solid Tumours
Interventions
RC88Drug
Every 2 weeks for a maximum of 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2DTime frame: 28 days after first treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Remegen
Beijing, Beijing Municipality, China
Remgenen
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.